TY - JOUR
T1 - A Double-Edged Sword—Cardiovascular Concerns of Potential Anti-COVID-19 Drugs
AU - Yu, Wen Liang
AU - Toh, Han Siong
AU - Liao, Chia Te
AU - Chang, Wei Ting
N1 - Funding Information:
This work was supported by Chi-Mei Medical Center.
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/4
Y1 - 2021/4
N2 - Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems including the cardiovascular system. Most importantly, in addition to the direct injury from the virus per se, the subsequent cytokine storm, an overproduction of immune cells and their activating compounds, causes devastating damage. To date, emerging anti-SARS-CoV-2 treatments are warranted to control epidemics. Several candidate drugs have been screened and are currently under investigation. These primarily include antiviral regimens and immunomodulatory regimens. However, beyond the anti-SARS-CoV-2 effects, these drugs may also have risks to the cardiovascular system, especially altering cardiac conduction. Herein, we review the cardiovascular risks of potential anti-COVID-19 drugs.
AB - Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems including the cardiovascular system. Most importantly, in addition to the direct injury from the virus per se, the subsequent cytokine storm, an overproduction of immune cells and their activating compounds, causes devastating damage. To date, emerging anti-SARS-CoV-2 treatments are warranted to control epidemics. Several candidate drugs have been screened and are currently under investigation. These primarily include antiviral regimens and immunomodulatory regimens. However, beyond the anti-SARS-CoV-2 effects, these drugs may also have risks to the cardiovascular system, especially altering cardiac conduction. Herein, we review the cardiovascular risks of potential anti-COVID-19 drugs.
KW - Complications
KW - COVID-19
KW - Potential cardiotoxicity
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85086649451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086649451&partnerID=8YFLogxK
U2 - 10.1007/s10557-020-07024-7
DO - 10.1007/s10557-020-07024-7
M3 - Review article
C2 - 32557011
AN - SCOPUS:85086649451
SN - 0920-3206
VL - 35
SP - 205
EP - 214
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
IS - 2
ER -